Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 485

1.

Clinicopathologic and immunophenotypic characterization of lichen planopilaris and central centrifugal cicatricial alopecia: A comparative study of 51 cases.

Jordan CS, Chapman C, Kolivras A, Roberts JL, Thompson NB, Thompson CT.

J Cutan Pathol. 2019 Oct 12. doi: 10.1111/cup.13592. [Epub ahead of print]

PMID:
31605498
2.

Veracity in the Review Process.

de Ru JA, Ward TN, Roberts JL.

Headache. 2019 Oct;59(9):1429-1433. doi: 10.1111/head.13671. No abstract available.

PMID:
31603555
3.

Correction: HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo.

Booth L, Roberts JL, Poklepovic A, Avogadri-Connors F, Cutler RE, Lalani AS, Dent P.

Oncotarget. 2019 Aug 20;10(49):5120-5122. doi: 10.18632/oncotarget.27162. eCollection 2019 Aug 20.

4.

Editor's Note: Regulation of OSU-03012 Toxicity by ER Stress Proteins and ER Stress-Inducing Drugs.

Booth L, Roberts JL, Cruickshanks N, Grant S, Poklepovic A, Dent P.

Mol Cancer Ther. 2019 Sep;18(9):1669. doi: 10.1158/1535-7163.MCT-19-0666. No abstract available.

PMID:
31481480
5.

The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib.

Booth L, Roberts JL, Poklepovic A, Dent P.

Front Oncol. 2019 Jul 18;9:650. doi: 10.3389/fonc.2019.00650. eCollection 2019.

6.

Equine Calming Products: A Short Survey Into Their Use, Effect, and Knowledge Using a Small Sample of Horse Owners in the North of Scotland, UK.

Ross DJ, Roberts JL.

J Equine Vet Sci. 2018 Sep;68:63-67. doi: 10.1016/j.jevs.2018.05.208. Epub 2018 May 26.

PMID:
31256891
7.

Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells.

Dent P, Booth L, Roberts JL, Liu J, Poklepovic A, Lalani AS, Tuveson D, Martinez J, Hancock JF.

Oncogene. 2019 Jul;38(30):5890-5904. doi: 10.1038/s41388-019-0849-8. Epub 2019 Jun 28.

PMID:
31253872
8.

Forensic genealogy and the power of defaults.

Ram N, Roberts JL.

Nat Biotechnol. 2019 Jul;37(7):707-708. doi: 10.1038/s41587-019-0172-5. No abstract available.

PMID:
31189937
9.

A Nudge Toward Meaningful Choice.

Fowler LR, Roberts JL.

Am J Bioeth. 2019 May;19(5):76-78. doi: 10.1080/15265161.2019.1588413. No abstract available.

PMID:
31090530
10.

Peptoid microsphere coatings: The effects of helicity, temperature, pH, and ionic strength.

Perez Bakovic GR, Roberts JL, Colford B, Joyce M, Servoss SL.

Biopolymers. 2019 Jun;110(6):e23283. doi: 10.1002/bip.23283. Epub 2019 Apr 22.

PMID:
31009076
11.

Rural and Urban Differences in the Adoption of New Health Information and Medical Technologies.

Haggstrom DA, Lee JL, Dickinson SL, Kianersi S, Roberts JL, Teal E, Baker LB, Rawl SM.

J Rural Health. 2019 Mar;35(2):144-154. doi: 10.1111/jrh.12358. Epub 2019 Mar 4.

PMID:
30830983
12.

NEDD4 over-expression regulates the afatinib resistant phenotype of NSCLC cells.

Booth L, Roberts JL, Poklepovic A, Dent P.

Oncol Signal. 2018 Jun;1(1):19-30. doi: 10.1016/j.onsig.2017.07.001. Epub 2017 Aug 16.

13.

Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gαq and Gα11 and kill uveal melanoma cells.

Booth L, Roberts JL, Sander C, Lalani AS, Kirkwood JM, Hancock JF, Poklepovic A, Dent P.

Cancer Biol Ther. 2019;20(5):700-710. doi: 10.1080/15384047.2018.1551747. Epub 2018 Dec 20.

PMID:
30571927
14.

Racial and Socioeconomic Disparities in Cancer-Related Knowledge, Beliefs, and Behaviors in Indiana.

Rawl SM, Dickinson S, Lee JL, Roberts JL, Teal E, Baker LB, Kianersi S, Haggstrom DA.

Cancer Epidemiol Biomarkers Prev. 2019 Mar;28(3):462-470. doi: 10.1158/1055-9965.EPI-18-0795. Epub 2018 Nov 28.

PMID:
30487135
15.

Essential Steps to Ensure Publication in Headache (and Any Other Journal of Good Repute).

Roberts JL.

Headache. 2018 Nov;58(10):1501-1502. doi: 10.1111/head.13440. No abstract available.

PMID:
30481385
16.

Recovery planning towards doubling wild tiger Panthera tigris numbers: Detailing 18 recovery sites from across the range.

Harihar A, Chanchani P, Borah J, Crouthers RJ, Darman Y, Gray TNE, Mohamad S, Rawson BM, Rayan MD, Roberts JL, Steinmetz R, Sunarto S, Widodo FA, Anwar M, Bhatta SR, Chakravarthi JPP, Chang Y, Congdon G, Dave C, Dey S, Durairaj B, Fomenko P, Guleria H, Gupta M, Gurung G, Ittira B, Jena J, Kostyria A, Kumar K, Kumar V, Lhendup P, Liu P, Malla S, Maurya K, Moktan V, Van NDN, Parakkasi K, Phoonjampa R, Phumanee W, Singh AK, Stengel C, Subba SA, Thapa K, Thomas TC, Wong C, Baltzer M, Ghose D, Worah S, Vattakaven J.

PLoS One. 2018 Nov 8;13(11):e0207114. doi: 10.1371/journal.pone.0207114. eCollection 2018.

17.

Fingolimod augments Pemetrexed killing of non-small cell lung cancer and overcomes resistance to ERBB inhibition.

Booth L, Roberts JL, Spiegel S, Poklepovic A, Dent P.

Cancer Biol Ther. 2019;20(5):597-607. doi: 10.1080/15384047.2018.1538616. Epub 2018 Nov 2.

PMID:
30388910
18.

Neratinib augments the lethality of [regorafenib + sildenafil].

Booth L, Roberts JL, Rais R, Cutler RE Jr, Diala I, Lalani AS, Hancock JF, Poklepovic A, Dent P.

J Cell Physiol. 2019 Apr;234(4):4874-4887. doi: 10.1002/jcp.27276. Epub 2018 Sep 10.

PMID:
30203445
19.

Palbociclib augments Neratinib killing of tumor cells that is further enhanced by HDAC inhibition.

Booth L, Roberts JL, Rais R, Cutler RE Jr, Diala I, Lalani AS, Poklepovic A, Dent P.

Cancer Biol Ther. 2019;20(2):157-168. doi: 10.1080/15384047.2018.1507665. Epub 2018 Sep 5.

20.

An ex-vivo model to determine dental pulp responses to heat and light-curing of dental restorative materials.

Lynch CD, Roberts JL, Al-Shehri A, Milward PJ, Sloan AJ.

J Dent. 2018 Dec;79:11-18. doi: 10.1016/j.jdent.2018.08.014. Epub 2018 Aug 31.

PMID:
30176259
21.

Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody.

Booth L, Roberts JL, Poklepovic A, Dent P.

Cancer Biol Ther. 2019;20(1):109-121. doi: 10.1080/15384047.2018.1507258. Epub 2018 Aug 24.

22.

Mixed methods process evaluation of an enhanced community-based rehabilitation intervention for elderly patients with hip fracture.

Roberts JL, Pritchard AW, Williams M, Totton N, Morrison V, Din NU, Williams NH.

BMJ Open. 2018 Aug 8;8(8):e021486. doi: 10.1136/bmjopen-2018-021486.

23.

Valproate augments Niraparib killing of tumor cells.

Booth L, Roberts JL, Rais R, Poklepovic A, Dent P.

Cancer Biol Ther. 2018;19(9):797-808. doi: 10.1080/15384047.2018.1472190. Epub 2018 Aug 1.

24.

Hip fracture in the elderly multidisciplinary rehabilitation (FEMuR) feasibility study: testing the use of routinely collected data for future health economic evaluations.

Williams NH, Mawdesley K, Roberts JL, Din NU, Totton N, Charles JM, Hoare Z, Edwards RT.

Pilot Feasibility Stud. 2018 May 7;4:76. doi: 10.1186/s40814-018-0269-5. eCollection 2018.

25.

Preferences of older patients regarding hip fracture rehabilitation service configuration: A feasibility discrete choice experiment.

Charles JM, Roberts JL, Ud Din N, Williams NH, Yeo ST, Edwards RT.

J Rehabil Med. 2018 Jul 17;50(7):636-642. doi: 10.2340/16501977-2350.

26.

Enterococcus faecalis Demonstrates Pathogenicity through Increased Attachment in an Ex Vivo Polymicrobial Pulpal Infection.

Nishio Ayre W, Melling G, Cuveillier C, Natarajan M, Roberts JL, Marsh LL, Lynch CD, Maillard JY, Denyer SP, Sloan AJ.

Infect Immun. 2018 Apr 23;86(5). pii: e00871-17. doi: 10.1128/IAI.00871-17. Print 2018 May.

27.

[Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration.

Booth L, Roberts JL, Rais R, Kirkwood J, Avogadri-Connors F, Cutler RE Jr, Lalani AS, Poklepovic A, Dent P.

Oncotarget. 2017 Dec 26;9(5):6062-6074. doi: 10.18632/oncotarget.23681. eCollection 2018 Jan 19.

28.

Transcriptional Mechanisms of Secondary Fracture Healing.

Roberts JL, Paglia DN, Drissi H.

Curr Osteoporos Rep. 2018 Apr;16(2):146-154. doi: 10.1007/s11914-018-0429-9. Review.

29.

Unconventional Approaches to Modulating the Immunogenicity of Tumor Cells.

Booth L, Roberts JL, Kirkwood J, Poklepovic A, Dent P.

Adv Cancer Res. 2018;137:1-15. doi: 10.1016/bs.acr.2017.11.004. Epub 2018 Jan 3.

30.

The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.

Booth L, Roberts JL, Samuel P, Avogadri-Connors F, Cutler RE, Lalani AS, Poklepovic A, Dent P.

Cancer Biol Ther. 2018 Jun 3;19(6):525-533. doi: 10.1080/15384047.2018.1436024. Epub 2018 Mar 6.

31.

TP53 is required for BECN1- and ATG5-dependent cell death induced by sphingosine kinase 1 inhibition.

Lima S, Takabe K, Newton J, Saurabh K, Young MM, Leopoldino AM, Hait NC, Roberts JL, Wang HG, Dent P, Milstien S, Booth L, Spiegel S.

Autophagy. 2018;14(6):942-957. doi: 10.1080/15548627.2018.1429875. Epub 2018 Mar 11.

32.

Observation of a strong-coupling effect on electron-ion collisions in ultracold plasmas.

Chen WT, Witte C, Roberts JL.

Phys Rev E. 2017 Jul;96(1-1):013203. doi: 10.1103/PhysRevE.96.013203. Epub 2017 Jul 7.

PMID:
29347164
33.

The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells.

Booth L, Roberts JL, Avogadri-Connors F, Cutler RE Jr, Lalani AS, Poklepovic A, Dent P.

Cancer Biol Ther. 2018 Mar 4;19(3):239-247. doi: 10.1080/15384047.2018.1423927. Epub 2018 Jan 22.

PMID:
29333953
34.

Curcumin interacts with sildenafil to kill GI tumor cells via endoplasmic reticulum stress and reactive oxygen/ nitrogen species.

Roberts JL, Poklepovic A, Booth L.

Oncotarget. 2017 Aug 2;8(59):99451-99469. doi: 10.18632/oncotarget.19807. eCollection 2017 Nov 21.

35.

The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib.

Booth L, Roberts JL, Poklepovic A, Kirkwood J, Sander C, Avogadri-Connors F, Cutler RE Jr, Lalani AS, Dent P.

Cancer Biol Ther. 2018 Feb 1;19(2):132-137. doi: 10.1080/15384047.2017.1394556. Epub 2017 Dec 8.

36.

HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo.

Booth L, Roberts JL, Poklepovic A, Avogadri-Connors F, Cutler RE, Lalani AS, Dent P.

Oncotarget. 2017 Oct 9;8(52):90262-90277. doi: 10.18632/oncotarget.21660. eCollection 2017 Oct 27. Erratum in: Oncotarget. 2019 Aug 20;10(49):5120-5122.

37.

HDAC inhibitors enhance the immunotherapy response of melanoma cells.

Booth L, Roberts JL, Poklepovic A, Kirkwood J, Dent P.

Oncotarget. 2017 May 17;8(47):83155-83170. doi: 10.18632/oncotarget.17950. eCollection 2017 Oct 10.

38.

Development of an evidence-based complex intervention for community rehabilitation of patients with hip fracture using realist review, survey and focus groups.

Roberts JL, Din NU, Williams M, Hawkes CA, Charles JM, Hoare Z, Morrison V, Alexander S, Lemmey A, Sackley C, Logan P, Wilkinson C, Rycroft-Malone J, Williams NH.

BMJ Open. 2017 Oct 11;7(10):e014362. doi: 10.1136/bmjopen-2016-014362.

39.

Patient Factors Associated with Shorter Length of Stay Following Total Hip Arthroplasty-A Retrospective Cohort Study.

Byrne PA, Gupta S, Hopper GP, Deakin AH, Roberts JL, Kinninmonth AWG.

Surg Technol Int. 2017 Oct 12;31:197-200.

PMID:
29020708
40.

Developing a multidisciplinary rehabilitation package following hip fracture and testing in a randomised feasibility study: Fracture in the Elderly Multidisciplinary Rehabilitation (FEMuR).

Williams NH, Roberts JL, Din NU, Charles JM, Totton N, Williams M, Mawdesley K, Hawkes CA, Morrison V, Lemmey A, Edwards RT, Hoare Z, Pritchard AW, Woods RT, Alexander S, Sackley C, Logan P, Wilkinson C, Rycroft-Malone J.

Health Technol Assess. 2017 Aug;21(44):1-528. doi: 10.3310/hta21440.

41.

[pemetrexed + sildenafil], via autophagy-dependent HDAC downregulation, enhances the immunotherapy response of NSCLC cells.

Booth L, Roberts JL, Poklepovic A, Dent P.

Cancer Biol Ther. 2017 Sep 2;18(9):705-714. doi: 10.1080/15384047.2017.1362511.

42.

Antibiotic utilisation in very low birth weight infants without sepsis or necrotising enterocolitis is associated with multiple adverse outcomes.

Roberts JL, Patel RM.

Evid Based Med. 2017 Oct;22(5):187. doi: 10.1136/ebmed-2017-110756. Epub 2017 Jul 12. No abstract available.

PMID:
28701373
43.

Negotiating Commercial Interests in Biospecimens.

Roberts JL.

J Law Med Ethics. 2017 Mar;45(1):138-141. doi: 10.1177/1073110517703107.

PMID:
28661280
44.

Clinical Care Guideline for Improving Pediatric Acute Musculoskeletal Infection Outcomes.

Spruiell MD, Searns JB, Heare TC, Roberts JL, Wylie E, Pyle L, Donaldson N, Stewart JR, Heizer H, Reese J, Scott HF, Pearce K, Anderson CJ, Erickson M, Parker SK.

J Pediatric Infect Dis Soc. 2017 Sep 1;6(3):e86-e93. doi: 10.1093/jpids/pix014.

PMID:
28419275
45.

The Impact of Nutritional Interventions beyond the First 2 Years of Life on Linear Growth: A Systematic Review and Meta-Analysis.

Roberts JL, Stein AD.

Adv Nutr. 2017 Mar 15;8(2):323-336. doi: 10.3945/an.116.013938. Print 2017 Mar. Review.

46.

The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo.

Booth L, Roberts JL, Sander C, Lee J, Kirkwood JM, Poklepovic A, Dent P.

Oncotarget. 2017 Mar 7;8(10):16367-16386. doi: 10.18632/oncotarget.14829.

47.

PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib].

Booth L, Roberts JL, Poklepovic A, Dent P.

Oncotarget. 2017 Feb 21;8(8):13464-13475. doi: 10.18632/oncotarget.14562.

48.

Should you profit from your genome?

Roberts JL, Pereira S, McGuire AL.

Nat Biotechnol. 2017 Jan 10;35(1):18-20. doi: 10.1038/nbt.3757. No abstract available.

PMID:
28072771
49.

Cucurbit[7]uril-Tetramethylrhodamine Conjugate for Direct Sensing and Cellular Imaging.

Bockus AT, Smith LC, Grice AG, Ali OA, Young CC, Mobley W, Leek A, Roberts JL, Vinciguerra B, Isaacs L, Urbach AR.

J Am Chem Soc. 2016 Dec 21;138(50):16549-16552. doi: 10.1021/jacs.6b11140. Epub 2016 Dec 8.

PMID:
27998093
50.

The Legality of Biometric Screening of Professional Athletes.

Roberts JL, Cohen IG, Deubert CR, Lynch HF.

Am J Bioeth. 2017 Jan;17(1):65-67. No abstract available.

PMID:
27996898

Supplemental Content

Loading ...
Support Center